NTRA · Natera, Inc.
Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-08-12 | Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers |
| 2026-08-06 | Natera Reports Second Quarter 2026 Financial Results |
| 2026-08-05 | Natera Submits Signatera™ to Japan’s PMDA for Approval as a Companion Diagnostic in Muscle-Invasive Bladder Cancer |
| 2026-07-30 | Natera to Report its Second Quarter Results on August 6, 2026 |
| 2026-07-22 | Signatera™ MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study |
| 2026-07-16 | Finalized MolDx LCD Includes Expanded Coverage for Natera’s Prospera™ Portfolio |
| 2026-07-09 | Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers |
| 2026-07-06 | Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer |
| 2026-06-29 | Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer |
| 2026-06-25 | Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial |
| 2026-06-24 | Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer |
| 2026-06-23 | NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update |
| 2026-06-18 | Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congress |
| 2026-06-04 | Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer |
| 2026-06-03 | Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors |
| 2026-05-29 | Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma |
| 2026-05-28 | Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer |
| 2026-05-26 | Natera to Launch Enhanced Panorama™ NIPT, Powered by Novel SNP-Informed Deep Sequencing Technology |
| 2026-05-21 | Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology |
| 2026-05-21 | Natera Announces Expansion in Austin, Creating What Is Believed to Be the Largest Sequencing Facility in the World |
| 2026-05-20 | EXPAND Trial of Natera’s Fetal Focus™ Single-Gene NIPT Surpasses >2,000 Patients Enrolled |
| 2026-05-15 | Signatera™ CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC) |
| 2026-05-07 |
Natera Reports First Quarter 2026 Financial Results
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2026. Recent Financial Highlights Generated total revenues of $696.6 million in the first quarter of 2026, compared to $501.8 million in the first quarter of 2025, an increase of 38.8%. Generated a gross margin 1 of 64.7% in the first quarter of 2026, compared to a gross margin 1 of 63.1% in the first quarter of 2025. Processed approximately 1,013,600 tests in the first quarter of 2026, compared to approximately 855,100 tests in the first quarter of 2025, an increase of 18.5%. Women’s Health generated the second highest quarterly unit growth since 2019 and Oncology delivered another record quarter for volume growth. Processed approximately 258,900 oncology tests in the first quarter of 2026, compared to approximately 167,700 in the first quarter of 2025, an increase of 54.4%. Achieved positive cash inflow of approximately $11.8 |
| 2026-04-30 |
Natera to Report its First Quarter Results on May 7, 2026
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its first quarter ended March 31, 2026, after the market closes on May 7, 2026. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information Event: Natera’s First Quarter 2026 Financial Results Date: May 7, 2026 Time: 1:30 p.m. PT (4:30 p.m. ET) Live Dial-In: 1-888-770-7321 (Domestic) 1-929-201-7107 (International) Conference ID: 7684785 Webcast: https://events.q4inc.com/attendee/443070230 A webcast replay will be available at investor.natera.com . About Natera Natera™ is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier |
| 2026-04-22 |
Prospera™ Evidence in Heart and Lung Transplantation Featured Across 17 Presentations at ISHLT
Broad evidence, including six oral presentations, highlights Prospera’s ability to enable earlier detection, refine risk stratification, and inform clinical decision-making in transplant care Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a broad body of evidence supporting its Prospera test at the 2026 International Society for Heart and Lung Transplantation (ISHLT) Annual Meeting. Prospera will be featured in 17 abstracts, including six oral presentations. Together with academic colleagues, Natera will highlight Prospera’s expanding clinical utility in heart and lung transplantation, spanning rejection surveillance, imaging correlation, and real-world clinical decision-making. Key highlights include: In heart transplant: Prospera Heart serial dynamics (increases/decreases) predicted a variety of adverse outcomes at 1-year post-transplant, in addition to rejection. Patients with a positive Prospera result were up to 4x more |